— Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested — — ALKS 2680 Was Generally Well Tolerated at All Doses Tested — — Vibrance-1 Phase 2 Study of ALKS 2680 in Patients With Narcolepsy Type 1 Is Ongoing — DUBLIN, June 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase 1b, proof-of-concept ...